High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial.

被引：0
|
作者：
Kasimis, B
Cogswell, J
Hwang, S
Chang, VT
Srinivas, S
Zhong, F
Duque, L
Morales, E
Boholli, I
Blumenfrucht, M
机构：
[1] VA NJ Hlth Care Syst, E Orange, NJ USA
[2] VA New Jersey Hlth Care Syst, E Orange, NJ USA
[3] Univ Med & Dent New Jersey, VA New Jersey Hlth Care Syst, E Orange, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428S / 428S
页数：1
相关论文
共 50 条
  • [41] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC)
    Huang, X.
    Ning, Y. M.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Mulquin, M.
    Madan, R. A.
    Bassim, C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [42] A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in hormone refractory prostate cancer (HRPC).
    Sinibaldi, V
    Carducci, M
    Moore-Cooper, S
    Laufer, M
    Zahurak, M
    Eisenberger, M
    ANNALS OF ONCOLOGY, 2000, 11 : 77 - 77
  • [43] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)
    Dreicer, R.
    Garcia, J.
    Smith, S.
    Elson, P.
    Triozzi, P.
    Hodnick, S.
    Rini, B.
    Klein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)
    Guastalla, JP
    Bonneterre, J
    Fumoleau, P
    Piccart, M
    Tubiana, M
    Chevallier, B
    Nieamann, C
    Alakl, M
    Nichol, A
    Riva, A
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 348 - 348
  • [46] A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    Breitz, H. B.
    Roman, L. A.
    Karlov, P. A.
    Cheporov, S. V.
    Lopatkin, N. D.
    Baker, G. S.
    Karlin, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC).
    Nelius, T.
    Klatte, T.
    Reiher, F.
    Filleur, S.
    Yap, R.
    Allhoff, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 254S - 254S
  • [48] A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
    Chi, K. N.
    Beardsley, E. K.
    Venner, P. M.
    Eigl, B. J.
    Hotte, S. J.
    Ko, Y.
    Saad, F.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Randomised study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [50] Multicenter phase II trial of S-1 in patients (PTS) with hormone-refractory prostate cancer (HRPC): The S-1 cooperative study group (prostate cancer)
    Akaza, Hideyuki
    Ikemoto, Isao
    Namiki, Mikio
    Usami, Michiyuki
    Kobayashi, Mikio
    Fujimoto, Hiroyuki
    Tsukamoto, Taiji
    Naito, Seiji
    ANNALS OF ONCOLOGY, 2006, 17 : 150 - 150
12345